Vivimed Labs Ltd

₹ 5.18 0.19%

24 Jul - close price

vivimedlabs.com BSE: 532660 NSE: VIVIMEDLAB

About

Vivimed Labs Ltd, established in 1988, is primarily engaged in the Business of Active Pharmaceuticals Ingredients, CDMO Finished Dosage Formulation, Specialty Chemicals and Retail Branded Formulation manufacturing.^[1]^[2]

Key Points

Special Resolution^[1]
In Dec'25, Under Special Resolution Company asked for approval for making an application to initiate a pre-packaged insolvency resolution process under the Insolvency and Bankruptcy Code, 2016, which was approved by shareholders.

Website BSE NSE - BE

Market Cap ₹ 43.0 Cr.
Current Price ₹ 5.18
High / Low ₹ 29.4 / 5.00
Stock P/E
Book Value ₹ -25.4
Dividend Yield 0.00 %
ROCE -65.2 %
ROE %
Face Value ₹ 2.00

Add ratio to table

Edit ratios

Pros

Cons

Company has low interest coverage ratio.
The company has delivered a poor sales growth of -39.5% over past five years.
Promoter holding is low: 7.57%
Contingent liabilities of Rs.183 Cr.
Company has high debtors of 236 days.
Promoter holding has decreased over last 3 years: -13.4%

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	37	35	34	41	39	29	25	37	26	21	21	16	12
	201	36	40	40	67	40	25	35	28	22	22	27	152
Operating Profit	-164	-0	-6	1	-28	-11	-1	1	-2	-0	-1	-11	-140
OPM %	-444%	-1%	-18%	3%	-74%	-37%	-3%	3%	-10%	-1%	-5%	-68%	-1,169%
	1	0	2	0	8	0	0	0	4	0	0	0	6
Interest	9	11	12	13	-33	0	0	0	2	1	2	1	1
Depreciation	96	5	5	5	6	4	4	7	6	5	5	5	12
Profit before tax	-268	-16	-20	-17	7	-15	-5	-6	-5	-5	-7	-17	-147
Tax %	-1%	0%	0%	-3%	21%	0%	0%	0%	2%	0%	0%	0%	0%
	-266	-16	-20	-16	5	-15	-5	-6	-6	-5	-7	-17	-147
EPS in Rs	-32.08	-1.88	-2.45	-1.94	0.63	-1.84	-0.62	-0.72	-0.68	-0.66	-0.88	-2.00	-17.74
Raw PDF

Profit & Loss

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,380	1,346	1,462	1,186	1,315	1,059	861	237	187	149	116	70
	1,156	1,111	1,057	971	1,135	1,049	830	245	374	182	129	222
Operating Profit	224	234	404	215	180	10	32	-8	-187	-33	-13	-152
OPM %	16%	17%	28%	18%	14%	1%	4%	-3%	-100%	-22%	-11%	-218%
	6	11	8	10	23	8	10	1	1	10	4	6
Interest	86	84	68	82	70	61	56	40	36	3	3	4
Depreciation	66	61	58	56	67	67	56	18	108	20	20	26
Profit before tax	78	100	286	86	66	-109	-70	-65	-331	-46	-32	-176
Tax %	7%	16%	25%	11%	13%	-0%	3%	4%	-1%	-1%	0%	0%
	72	84	214	76	57	-109	-72	-68	-329	-45	-32	-176
EPS in Rs	8.90	10.33	26.41	9.44	6.95	-13.16	-8.67	-8.16	-39.62	-5.48	-3.85	-21.28
Dividend Payout %	0%	0%	2%	4%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-26%
5 Years:	-39%
3 Years:	-28%
TTM:	-40%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	14%
TTM:	-452%

Stock Price CAGR
10 Years:	-24%
5 Years:	-26%
3 Years:	1%
1 Year:	%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	%

Balance Sheet

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	16	16	16	17	17	17	17	17	17	17	17	17
Reserves	479	505	718	885	602	493	415	348	23	-22	-52	-227
	1,076	1,015	1,011	1,149	1,280	1,268	326	359	379	377	376	397
	327	519	317	343	431	432	532	543	658	579	580	567
Total Liabilities	1,898	2,055	2,062	2,394	2,329	2,210	1,289	1,266	1,076	950	921	753
	813	814	879	1,035	965	1,045	502	520	436	418	408	386
CWIP	90	94	76	65	122	89	60	40	21	21	17	18
Investments	3	3	3	3	3	86	199	199	199	168	168	181
	992	1,144	1,104	1,290	1,239	990	529	507	421	343	328	170
Total Assets	1,898	2,055	2,062	2,394	2,329	2,210	1,289	1,266	1,076	950	921	753

Cash Flows

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025
	140	154	58	21	422	80	567	28	35	-24	-2
	-107	-190	-68	-164	-89	-196	404	-16	-5	28	-5
	-42	41	35	186	-338	72	-1,015	-10	-34	-6	5
Net Cash Flow	-8	4	25	44	-5	-44	-44	1	-3	-2	-1
Free Cash Flow	16	95	-11	-142	333	-33	1,084	11	30	-26	-6
CFO/OP	63%	66%	23%	30%	243%	972%	1,720%	-352%	-19%	73%	13%

Ratios

Consolidated Figures in Rs. Crores / View Standalone

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	87	88	50	85	99	86	46	134	145	203	233	236
Inventory Days	244	294	329	411	397	396	263	573	216	327	358	63
Days Payable	107	98	122	154	207	179	35	100	74	225	240	263
Cash Conversion Cycle	224	285	258	342	288	303	274	607	286	305	351	36
Working Capital Days	43	58	55	121	68	216	77	195	-15	-171	-255	-1,468
ROCE %	11%	12%	22%	9%	7%	-3%	-1%	-3%	-52%	-11%	-8%	-65%

Insights

In beta

Mar 2017

Mar 2018

Mar 2019

Mar 2020

Mar 2021

Mar 2022

Mar 2024

Mar 2025

Permanent Employees
employees ・Standalone data

	xxx	xxx	xxx	xxx	xxx	xxx	xxx
xx	xx	xx	xx			x	x
x	x	x	x		x	x
	xxx	xxx
		xx	xx
		xx	xx
	xxx			xxx
	xx	xx

Please log in to see hidden values.

Number of Manufacturing Facilities
facilities

Number of R&D Centres
centres

Active DMFs Filed Worldwide
DMFs

Countries Served (Overall)
countries

Distributor Arrangements (UQUIFA/API)
distributors

Reactor Capacity (UQUIFA/API)
KL

Type II DMFs Filed with USFDA
DMFs

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	20.94%	7.76%	7.76%	7.76%	7.57%
	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%	1.64%
	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
	77.30%	77.29%	77.30%	77.29%	77.30%	77.30%	77.30%	77.30%	90.47%	90.47%	90.47%	90.66%
No. of Shareholders	49,503	49,038	49,027	49,016	49,012	49,003	49,005	48,957	48,928	48,925	49,221	47,492

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	36.48%	36.64%	34.39%	32.79%	28.57%	21.98%	20.94%	20.94%	20.94%	7.57%
	4.23%	5.24%	4.07%	3.56%	3.10%	1.64%	1.64%	1.64%	1.64%	1.64%
	0.33%	0.30%	0.48%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%	0.12%
	58.85%	57.71%	60.94%	63.53%	68.21%	76.27%	77.30%	77.29%	77.30%	90.66%
No. of Shareholders	19,274	30,575	33,380	30,638	37,989	53,110	50,683	49,016	48,957	47,492

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Credit ratings

Concalls

Aug 2019

Transcript

AI Summary
PPT
Mar 2019

Transcript

AI Summary
PPT
Nov 2018

Transcript

AI Summary
PPT
Aug 2018

Transcript

AI Summary
PPT
Jun 2018

Transcript

AI Summary
PPT
Feb 2018

Transcript

AI Summary
PPT
Nov 2017

Transcript

AI Summary
PPT
Aug 2017
Transcript PPT
Nov 2016
Transcript PPT
Aug 2016
Transcript PPT
May 2016
Transcript PPT
Aug 2015

Transcript

AI Summary
PPT